insights_auto
Why is PLX down 2.96%?
Dive Deeperchevron_right
PLX:NYSEAMERICAN
Protalix Biotherapeutics Inc
$2.62
arrow_downward
-2.96%(-0.080) 1D
$2.58
arrow_downward
-1.48% (-0.039)bedtimeAfter hours
Closed: Oct 16, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PLX...
Open
$2.70
High
$2.70
Low
$2.61
Mkt. cap
211.10M
Avg. vol.
868.88K
Volume
1.19M
P/E ratio
11.58
52-wk high
$3.19
52-wk low
$1.60
EPS
$0.23
Beta
-0.09
Shares outstanding
80.57M
No. of employees
226
Open
$2.70
High
$2.70
Low
$2.61
Mkt. cap
211.10M
Avg. vol.
868.88K
Volume
1.19M
P/E ratio
11.58
52-wk high
$3.19
52-wk low
$1.60
EPS
$0.23
Beta
-0.09
Shares outstanding
80.57M
No. of employees
226
News stories
From web sources and news partners
AskTraders.com
·
8 minutes ago
S&P 500 Can Absorb Fed Hikes, Says UBS CIO After Hot US Inflation
Interest.co.nz
·
12 minutes ago
Limited global currency moves although the NZD reached an October high
Benzinga
·
59 minutes ago
Dow Jones, Nasdaq 100, S&P 500 Outlook: Top Catalysts to Move US Stocks This Week
Yahoo Finance UK
·
4 hours ago
Yardeni Lowers S&P 500 Target to 7,900 Despite Maintaining 2027 Earnings Forecast
Profile
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease. Wikipedia
About Protalix Biotherapeutics Inc
CEODror Bashan
Employees226
Founded1993
HeadquartersKarmiel, North District, Israel
SectorBiotechnology
Websiteprotalix.com